Funds and ETFs ProPhase Labs, Inc.

Equities

PRPH

US74345W1080

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
4.71 USD -4.85% Intraday chart for ProPhase Labs, Inc. -10.46% +4.20%

ETFs positioned on ProPhase Labs, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.20% 27 M€ -5.03% -
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. PRPH Stock
  4. Funds and ETFs ProPhase Labs, Inc.